Results 91 to 100 of about 18,708 (185)

Efficacy and safety of sacubitril/valsartan in end-stage renal disease patients with heart failure: a review

Annals of Medicine
Purpose End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and ...
Peiyun Li, Yupei Li, Ling Zhang
doaj   +1 more source

Correction to ‘Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting’

ESC Heart Failure, Volume 12, Issue 2, Page 1525-1525, April 2025.
wiley   +1 more source

Valsartan [PDF]

, 2020
openaire   +1 more source

Higher persistence with valsartan compared with enalapril in daily practice

Vascular Health and Risk Management, 2008
Satu J Siiskonen1, Nancy S Breekveldt-Postma1, Gábor Vincze2, Zeba M Khan3, Joëlle A Erkens1, Ron MC Herings11PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands; 2Novartis Pharma AG, Basel, Switzerland; 3Novartis ...
Satu J Siiskonen, Nancy S Breekveldt-Postma, Gábor Vincze, Zeba M Khan, Joëlle A Erkens, et al   +5 more
doaj  

Incremental effects of vericiguat added to sacubitril/valsartan in heart failure with nonpreserved ejection fraction: a real-world study. [PDF]

Int J Cardiol Heart Vasc
Kinoshita H, Kimura K, Masada K, Shimonaga T, Sugino H.   +4 more
europepmc   +1 more source

Efficacy and safety of sacubitril/valsartan in patients on peritoneal dialysis: a systematic review and meta-analysis. [PDF]

J Bras Nefrol
Silva CLD, Fonseca PEO, Calice-Silva V, Ponce D, Rocha PN, Guimarães MG.   +5 more
europepmc   +1 more source

Efficacy and Safety of SPH3127 Tablet, a Novel Direct Renin Inhibitor, in Patients with Mild-to-Moderate Essential Hypertension: A Phase III Randomised Trial. [PDF]

Drugs
Lv Q, Ma C, Wang F, Li L, Xiong G, Li Z, Qu Y, Pang W, Xiao W, Ruan H, Wei L, Liu G, Zhang J, Liu Q, Lin L, Long M, Li H, Yuan H, Liu L, Gao Y, Liu P, Zhang C, Wang Z, Xie J, Wang J, Zhang X, Lu Y, Huang K, Liu M, Chen J, Gao X, Wang D, Ma X, Chen X, Li Y, Zhang Y, Kong X, Chen F, Zhang X, Qi J, Cao Y, Huang Y, Zhang Y, Cui W.   +43 more
europepmc   +1 more source

Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure. [PDF]

Circ Heart Fail
Gupta DK, Stevenson LW, Garner EM, Maulion C, Nian H, Wright PR, Turcu AF, Wei S, Brown NJ.   +8 more
europepmc   +1 more source

Correction: Sacubitril/Valsartan for Refractory Hypertension in Acute Intracerebral Hemorrhage: A Single-Center Retrospective Study. [PDF]

Cureus
Ito K, Sato S, Kawashima A, Kawamata T, Niimi Y.   +4 more
europepmc   +1 more source

Drug-Drug Interaction of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan: An Open-Label, Single-Center, Self-Control, 3-Period Study. [PDF]

Drug Des Devel Ther
Sheng L, Li X, Yu J, Yang X, Li H, Xu H.
europepmc   +1 more source